Holen Sie sich die Stockscreener-App
3.355
19.25%
0.55
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Replimune Group, Inc. (REPL) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Iovance climbs after FDA rejection for Replimune’s skin cancer drug - MSN
Replimune stock rebounds despite downgrades (REPL:NASDAQ) - Seeking Alpha
Fraud Investigation Opened: Levi & Korsinsky Investigates Replimune Group, Inc. (REPL) on Behalf of Shareholders - ACCESS Newswire
What analysts say about Replimune Group Inc. stockBreakthrough wealth creation - Autocar Professional
Replimune Shares Collapse After FDA Rejects Melanoma Therapy Application - MSN
What drives Replimune Group Inc. stock priceExplosive trading opportunities - Autocar Professional
Replimune receives CRL on BLA for RP1 for advanced melanoma - pharmaphorum
Replimune says FDA rejected its lead drug for skin cancer - MSN
INVESTOR ALERT: Investigation of Replimune Group, Inc. (REPL) Announced by Holzer & Holzer, LLC - GlobeNewswire
Lost Money on Replimune Group, Inc. (REPL)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
BMO Capital downgrades Replimune stock to Underperform after CRL - Investing.com Australia
Did You Suffer Losses in Replimune Group, Inc. (REPL)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
Replimune Group Surges to 445th in Trading Volume with $255 Million Day Despite 77 Percent Stock Drop - AInvest
Barclays downgrades Replimune Group stock rating to Equalweight on FDA rejection - Investing.com
Replimune CRL Could Hold Warning For Accelerated Approvals - insights.citeline.com
Replimune (REPL) Faces Downgrade and Uncertainty in Latest Analy - GuruFocus
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Business Wire
FDA Rejection Shocks Wall Street, And Craters A Stock - Investor's Business Daily
FDA Issues CRL for RP1 in Advanced Melanoma - Targeted Oncology
Earnings Misses And Clinical Hurdles Rattle Major Stocks - Finimize
BMO Capital reiterates Outperform rating on Replimune stock despite FDA setback By Investing.com - Investing.com South Africa
REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm - Business Wire
Replimune Group Inc. Stock Analysis and ForecastExceptional market performance - jammulinksnews.com
Market Analysis: July 22nd, 2025 - The Globe and Mail
Leerink Partners downgrades Replimune stock on FDA rejection letter By Investing.com - Investing.com Canada
REPL ALERT: Levi & Korsinsky Investigates Replimune Group, Inc. on Behalf of Shareholders Who Lost Money - ACCESS Newswire
Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program (NASDAQ:REPL) - Seeking Alpha
Replimune Group Inc. Stock (REPL) Opinions on FDA Drug Rejection - Quiver Quantitative
Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight - GlobeNewswire Inc.
Replimune (REPL) Downgraded to Market Perform by Leerink | REPL Stock News - GuruFocus
Replimune Group Stock Drops Significantly on News of FDA Complete Response LetterKehoe Law Firm, P.C. Investigating Securities Claims on Behalf of InvestorsREPL - ACCESS Newswire
Jefferies lowers Replimune Group stock price target to $6 from $31 - Investing.com India
Replimune drug rejected by FDA; Omega raises $647M biotech fund - BioPharma Dive
Replimune price target lowered to $6 from $31 at Jefferies - TipRanks
Wedbush downgrades Replimune stock to Neutral after FDA rejection By Investing.com - Investing.com South Africa
Barclays maintains Overweight rating on Replimune stock after FDA setback - Investing.com Australia
Replimune Group (REPL) Faces Downgrade with Significant Price Ta - GuruFocus
Replimune Plunges 76.26% Intraday, What Lies Behind the FDA's CRL Rejection? - AInvest
Replimune stock falls after FDA issues CRL for melanoma treatment - Investing.com
Replimune stock falls after FDA issues CRL for melanoma treatment By Investing.com - Investing.com Canada
Wedbush downgrades Replimune stock to Neutral after FDA rejection - Investing.com Australia
JPMorgan downgrades Replimune to Neutral following CRL for cancer drug - TipRanks
BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities - GlobeNewswire
Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment - Barron's
Rosen Law Firm Encourages Replimune Group, Inc. Investors to Inquire About Securities Class Action Investigation – REPL - Business Wire
Iovance stock gains as Replimune drug rejected (IOVA:NASDAQ) - Seeking Alpha
Replimune Group Plunges 73.3% Intraday, What Now for Replimune's Melanoma Gamble? - AInvest
Replimune rocked by CRL for lead candidate - The Pharma Letter
Mizuho analyst comments on Replimune stock decline following CRL By Investing.com - Investing.com Canada
Replimune (REPL) Group Trading Resumes After Halt | REPL Stock N - GuruFocus
Replimune (REPL) Downgraded After FDA Issues Complete Response L - GuruFocus
FDA Rejects Replimune’s Skin Cancer Treatment, Shares Sink - Yahoo Finance
Replimune Group Plunges 72.41% Intraday, Can the Biotech Rebound from FDA Rejection? - AInvest
Replimune stock downgraded by Cantor Fitzgerald after FDA rejection - Investing.com UK
Replimune (REPL) Trading Halted Due to Volatility | REPL Stock N - GuruFocus
BMO Capital reiterates Outperform rating on Replimune stock despite FDA setback - Investing.com Australia
FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks - Benzinga
Barclays maintains Overweight rating on Replimune stock after FDA setback By Investing.com - Investing.com UK
Replimune downgraded to Neutral from Overweight at Cantor Fitzgerald - TipRanks
REPL Soars: Ride the Momentum? - timothysykes.com
Replimune's Regulatory Setback and Strategic Path Forward: Assessing Long-Term Value Amid Short-Term Volatility in a High-Stakes Biotech Environment - AInvest
Replimune Group Receives FDA Complete Response Letter - TipRanks
Replimune Group Plunges 77.36% After FDA Rejects RP1 - AInvest
Replimune stock plunges after FDA rejects melanoma treatment application By Investing.com - Investing.com UK
Replimune stock plunges after FDA rejects melanoma treatment application - Investing.com
4.74%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):